Literature DB >> 19288123

Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas.

A Relic1, M Scheich, J Stapf, C Voelter, F Hoppe, R Hagen, L Pfreundner.   

Abstract

Induction chemotherapy followed by primary radiotherapy in responders is considered an alternative to surgery for advanced cancer of the larynx and hypopharynx (LHC). Comparison of therapeutic approaches is challenging and must respect oncological and functional outcome as well as quality of life during and after treatment. One aspect of primary radiochemotherapy is the option of salvage surgery in case of residual tumor. The outcome after salvage surgery following new organ-preserving strategies has to be examined. All patients undergoing induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy from 01/96 to 07/05 were included. Salvage surgery was performed either for local recurrence or suspected persistent nodal disease. Complete tumor removal, perioperative morbidity, and overall survival were analyzed in a retrospective study. 28 out of 134 patients underwent salvage surgery after primary treatment with induction chemotherapy and radiotherapy for advanced LHC. 15 patients had laryngectomy (LE) with neck dissection (ND), while 1 patient had lasersurgical partial laryngeal resection with ND for local recurrences. Twelve patients had salvage ND for suspicion of persistent lymph node metastases. 73% of LE patients had major postoperative problems such as pharyngocutaneous fistulas. In 56% of the cases, tumor removal turned out to be microscopically incomplete. Eight out of 12 patients who underwent salvage ND because of suspicious lymph nodes (66%) were free of vital tumor. When metastatic disease was present in the neck (4/12), recurrences occurred in 75% during postoperative follow-up. Only 2 out of 20 patients undergoing surgery for histologically proven recurrence after radiochemotherapy (10%) are actually tumor-free and alive after a mean observation time of 43.9 months. Salvage surgery for local recurrence is associated with high morbidity and poor oncological and functional outcome. ND for suspicious persistent nodal disease after radiochemotherapy can be an over-treatment. In our patients, it was burdened with cervical recurrences and distant metastases in presence of histologically confirmed lymph node metastases. In the light of our results, unfavourable outcome after salvage surgery must be pointed out when initially informing patients about different therapeutic options for advanced LHC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288123     DOI: 10.1007/s00405-009-0946-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  46 in total

1.  Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck.

Authors:  Stanley L Liauw; Robert J Amdur; Christopher G Morris; John W Werning; Douglas B Villaret; William M Mendenhall
Journal:  Head Neck       Date:  2007-08       Impact factor: 3.147

2.  Postoperative complications of salvage total laryngectomy.

Authors:  Ian Ganly; Snehal Patel; Jeanette Matsuo; Bhuvanesh Singh; Dennis Kraus; Jay Boyle; Richard Wong; Nancy Lee; David G Pfister; Ashok Shaha; Jatin Shah
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

3.  Elective neck dissection during salvage laryngectomy.

Authors:  Mike Yao; Jeremy C Roebuck; F Christopher Holsinger; Jeffery N Myers
Journal:  Am J Otolaryngol       Date:  2005 Nov-Dec       Impact factor: 1.808

4.  Salvage surgery after failure of nonsurgical therapy for carcinoma of the larynx and hypopharynx.

Authors:  S J Stoeckli; A B Pawlik; M Lipp; A Huber; S Schmid
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-12

5.  Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.

Authors:  Laura A Goguen; Marshall R Posner; Roy B Tishler; Lori J Wirth; Charles M Norris; Donald J Annino; Christopher A Sullivan; Yi Li; Robert I Haddad
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-05

6.  Coronal sections of larynges from radiation-therapy failures: a clinical-pathologic study.

Authors:  J H Brandenburg; K G Condon; T W Frank
Journal:  Otolaryngol Head Neck Surg       Date:  1986-09       Impact factor: 3.497

7.  Selective lymph node dissection following hyperfractionated accelerated radio-(chemo-)therapy for advanced head and neck cancer.

Authors:  Thomas Hehr; Johannes Classen; Ulrike Schreck; Stefan Glocker; Assen Koitschev; Michael Bamberg; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2002-07       Impact factor: 3.621

8.  Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck.

Authors:  J H Lee; M Machtay; L D Unger; G S Weinstein; R S Weber; A A Chalian; D I Rosenthal
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1998-08

9.  Surgery after organ preservation therapy. Analysis of wound complications.

Authors:  A M Sassler; R M Esclamado; G T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1995-02

10.  Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.

Authors:  G T Wolf; S G Fisher
Journal:  Laryngoscope       Date:  1992-08       Impact factor: 3.325

View more
  8 in total

1.  [Grafts with microvascular anastomosis. Their use in the head and neck region following radiotherapy and vessel depletion].

Authors:  K Zaoui; P Federspil; P K Plinkert; C Simon
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

2.  To do or not to do: salvage management for hypopharyngeal cancer after chemoradiation therapy.

Authors:  Pei-Hsin Chu; Ngan-Ming Tsang; Li-Ang Lee; Chun-Ta Liao; Tuan-Jen Fang
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-20       Impact factor: 2.503

3.  Transoral robotic-assisted free flap reconstruction after radiation therapy in hypopharyngeal carcinoma: report of two cases.

Authors:  Stéphane Hans; Thomas Jouffroy; David Veivers; Caroline Hoffman; Angélique Girod; Cécile Badoual; Jose Rodriguez; Daniel Brasnu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-28       Impact factor: 2.503

Review 4.  Is elective neck dissection indicated during salvage surgery for head and neck squamous cell carcinoma?

Authors:  Alvaro Sanabria; Carl E Silver; Kerry D Olsen; Jesus E Medina; Marc Hamoir; Vinidh Paleri; Vanni Mondin; Alessandra Rinaldo; Juan P Rodrigo; Carlos Suárez; Carsten C Boedeker; Michael L Hinni; Luiz P Kowalski; Afshin Teymoortash; Jochen A Werner; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-11       Impact factor: 2.503

5.  Assessment of peri- and postoperative complications and Karnofsky-performance status in head and neck cancer patients after radiation or chemoradiation that underwent surgery with regional or free-flap reconstruction for salvage, palliation, or to improve function.

Authors:  Christian Simon; Cem Bulut; Philippe A Federspil; Marc W Münter; Katja Lindel; Zazie Bergmann; Serkan Sertel; Sarah Leitzbach; Peter K Plinkert
Journal:  Radiat Oncol       Date:  2011-09-06       Impact factor: 3.481

Review 6.  Outcomes of anterolateral thigh flap reconstruction for salvage laryngopharyngectomy for hypopharyngeal cancer after concurrent chemoradiotherapy.

Authors:  Wei F Chen; Kai-Ping Chang; Chih-Hao Chen; Victor Bong-Hang Shyu; Huang-Kai Kao
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

7.  Systemic therapy strategies for head-neck carcinomas: Current status.

Authors:  Thomas K Hoffmann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

Review 8.  Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review.

Authors:  L Putten; R Bree; P A Doornaert; J Buter; S E J Eerenstein; D H F Rietveld; D J Kuik; C R Leemans
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-06       Impact factor: 2.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.